Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364975 | 1.00 | RAB9A (0.63) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL11907503 | 1.00 | RAB9A (0.63) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL11907502 | 1.00 | RAB9A (0.63) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL1364978 | 1.00 | RAB9A (0.63) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL13614205 | 0.94 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL29004577 | 0.94 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL29004578 | 0.94 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL4617880 | 0.94 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL4337454 | 0.94 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL10071672 | 0.94 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120209011-A1 | NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF | ASWATHANARAYANAPPA CHANDRASHEKAR (IN) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120209011-A1 | NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF | PTGER3, CBR3, PTGES3 | RAB9A 3612/4885KDM4E 4498/4885NPC1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.